Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Rani Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on developing oral biologic therapies that aim to replace injectable drug delivery. The company operates within the biopharmaceutical and drug delivery technology industries, with a core emphasis on transforming how large-molecule drugs such as peptides, proteins, and antibodies are administered. Its primary value proposition is enabling oral dosing for therapies traditionally limited to injections, targeting chronic diseases that require long-term treatment.
The company’s business centers on its proprietary RaniPill™ technology platform, which is designed to deliver biologics orally by releasing a drug payload directly into the intestinal wall. Rani Therapeutics was founded in 2012 and later went public in 2021. Since inception, the company has evolved from early technology development into a clinical-stage organization advancing multiple drug candidates, both proprietary and partnered, across endocrinology, gastroenterology, and immunology indications.
Business Operations
Rani Therapeutics generates value primarily through the development of proprietary drug candidates and through collaboration and licensing agreements with large pharmaceutical partners. Its operations are organized around the development of oral formulations of existing injectable drugs using the RaniPill™ capsule, which incorporates mechanical, chemical, and biologic components to enable drug delivery without needles. The company does not currently generate commercial product revenue and remains dependent on research funding, milestone payments, and capital markets.
The company’s pipeline includes both wholly owned programs and partnered assets. Key partnered programs have involved collaborations with pharmaceutical companies to develop oral versions of established biologics. Rani Therapeutics operates primarily in the United States, with research, development, and manufacturing capabilities supporting clinical trials. Manufacturing activities are focused on producing clinical-stage capsules and drug-device combination products rather than large-scale commercial supply.
Strategic Position & Investments
Rani Therapeutics’ strategy is centered on positioning its RaniPill™ platform as a differentiated oral delivery solution for biologics, addressing patient adherence challenges and expanding the lifecycle value of injectable drugs. Growth initiatives include advancing internal clinical programs, expanding the range of molecules compatible with its platform, and securing additional pharmaceutical partnerships that provide non-dilutive capital and validation.
The company has made targeted investments in proprietary device engineering, formulation science, and manufacturing capabilities to retain control over its core technology. Strategic collaborations have historically included partnerships with large pharmaceutical companies for molecules targeting metabolic and inflammatory diseases. Rani Therapeutics is also exploring next-generation capsule designs to broaden payload capacity and improve delivery efficiency, reflecting its focus on emerging drug-device combination technologies.
Geographic Footprint
Rani Therapeutics is headquartered in the United States, with its principal executive offices located in California. The company’s operations are primarily U.S.-based, including research, development, and manufacturing activities that support its clinical programs.
While Rani Therapeutics does not maintain a broad international operational footprint, its strategic influence extends globally through pharmaceutical partnerships and the potential applicability of its technology to worldwide biologics markets. Clinical development activities are conducted in compliance with U.S. regulatory standards, with the expectation that successful products could be commercialized across North America, Europe, and other major pharmaceutical markets through partners.
Leadership & Governance
Rani Therapeutics was founded by Tal Z. Gilboa, who conceived the company’s core technology and continues to influence its strategic direction. The leadership team brings together expertise in biotechnology, medical devices, and pharmaceutical development, with an emphasis on disciplined clinical execution and long-term platform value creation.
Key executives include:
- Tal Z. Gilboa – Founder and Chief Executive Officer
- Willard Dere – Chief Financial Officer
- Rakesh Patel – Chief Medical Officer
- Amar Sawhney – Chairman of the Board
The leadership philosophy emphasizes innovation in patient-centric drug delivery, strategic partnerships with established pharmaceutical companies, and rigorous adherence to regulatory and clinical development standards.